This article was downloaded by: On: *16 January 2011* Access details: *Access Details: Free Access* Publisher *Taylor & Francis* Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Journal of Immunoassay and Immunochemistry

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597271

# Application of an Enzyme Immunoassay to Monitor Bacterial Binding and to Measure Inhibition of Binding to Different Types of Solid Surfaces

Yasmin El Tahir<sup>ab</sup>; Paavo Toivanen<sup>b</sup>; Mikael Skurnik<sup>a</sup>

<sup>a</sup> Turku Centre for Biotechnology, University of Turku and Åbo Akadami University, Turku, Finland <sup>b</sup> Department of Medical Microbiology, University of Turku and Åbo Akadami University, Turku, Finland

**To cite this Article** Tahir, Yasmin El, Toivanen, Paavo and Skurnik, Mikael(1997) 'Application of an Enzyme Immunoassay to Monitor Bacterial Binding and to Measure Inhibition of Binding to Different Types of Solid Surfaces', Journal of Immunoassay and Immunochemistry, 18: 2, 165 — 183 **To link to this Article: DOI:** 10.1080/01971529708005811

**URL:** http://dx.doi.org/10.1080/01971529708005811

# PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# APPLICATION OF AN ENZYME IMMUNOASSAY TO MONITOR BACTERIAL BINDING AND TO MEASURE INHIBITION OF BINDING TO DIFFERENT TYPES OF SOLID SURFACES

Yasmin El Tahir<sup>1,2\*</sup>, Paavo Toivanen<sup>2</sup> and Mikael Skurnik<sup>1</sup>

Turku Centre for Biotechnology<sup>1</sup> and Department of Medical Microbiology<sup>2</sup>, University of

Turku and Åbo Akadami University, Fin-20521, Turku, Finland

# ABSTRACT

We describe the application of an enzyme immunoassay (EIA) for detecting bacteria bound to a solid surface. Different Yersinia enterocolitica and Escherichia coli strains, expressing the YadA protein, type 1 or type P fimbriae were used as models for this study. The assay was used to detect bacteria bound to fixed tissues or to glass slides coated with extracellular matrix molecules (collagen, laminin or fibronectin). E. coli specific antiserum (B357, Dakopatts, Glostrup, Denmark) and peroxidase conjugated antiserum (P217) were used to detect all E. coli strains used in the study. The bacterial binding could be monitored with a linear detection range between  $10^5$  and  $10^8$  bacteria. Most importantly, dose dependent inhibition of bacterial binding by soluble extracellular matrix molecules could be measured. (KEY WORDS: Bacterial adhesion, E. coli, Extracellular matrix molecules, Fimbriae, Yersinia, YadA)

## **INTRODUCTION**

Adherence of bacteria to a host target is a prerequisite for the initiation of the disease process [1]. Bacterial molecular constituents, in addition to host components, have been implicated in the binding and adhesion [1]. Enteric bacteria produce binding components (adhesins), together with other important molecules such as lipopolysaccharides, flagellae and porins as part of the bacterial outer membrane [1-3]. Because adherence is a key step in bacterial virulence [4], much interest has been focused on adherence assays. Both qualitative and quantitative methods to study adhesion of micro-organisms have been used. Quantitative methods are necessary to compare adhesion of different bacterial species or mutants and in inhibition experiments. Measurement of adhesion to cultured epithelial cells is a widely used method to evaluate microbial adhesion [5, 6].

Quantitation of adhesion has been performed in a number of ways: i) by the direct counting of adherent bacteria per epithelial cell using light microscopy [7-9], ii) by determining the adhering radioactivity using radiolabelled bacteria [10], and iii) by counting colony-forming units after recovery of adherent bacteria [11-13]. Adhesion tests using biological tissue sections as targets have also been developed [14-17]. Alternatively, solid surfaces coated with extracellular matrix molecules have been used as targets in bacterial binding assays [18-21].

In a recent report [22] we studied the binding of Yersinia enterocolitica to fixed tissue sections of human intestine, and for inhibition assays we applied a combination of immunohistochemical staining and enzyme immunoassay (EIA). We felt, however, that this method could be generally applicable to many different bacterial systems, especially in competition experiments, and therefore in the present work we used two species, Y. enterocolitica and E. coli as model organisms.

#### MATERIALS AND METHODS

## Bacterial strains and culture conditions

Bacterial strains used in this study are shown in Table 1. Y. enterocolitica strains (YeO3 and YeO3-c) were grown to stationary phase overnight at 37 °C in 10 ml of MedECa (0.1 g of MgSO<sub>4</sub> x 7H<sub>2</sub>O, 2 g of citric acid, 10 g of K<sub>2</sub>HPO<sub>4</sub>, 3.5 g of NaNH<sub>4</sub>HPO<sub>4</sub> x 4H<sub>2</sub>O, 1 mg vitamin B<sub>1</sub> per litre, containing 0.2% glucose, 0.2% casamino acids, and 2.5 mM CaCl<sub>2</sub>) [23]. E. coli strain C600/pYMS4514 was grown to stationary phase overnight at 37°C in 10 ml MedECa containing 10 µg of chloramphenicol per ml. E.

TABLE	1.
-------	----

Bacterial strains	Comments	Re f.
 Y. enterocolitica:		
6471/76 (YeO3)	scrotype O:3, virulence plasmid positive (pYV <sup>+</sup> ), patient isolate. $pYV$ carries the und f gaps when grown at $37^{\circ}C$	[29
6471/76-c (YeO3-c)	pYV <sup>-</sup> derivative of YeO3	[29 ]
E. con : C600	thi thr leu tonA lacY supE	[30
HB101	Δgpt- proA leu6 thi1 lacY1 galK2 ara14 xy15 mtl1 hsdS phx recA supE44 rpsL	[31 ]
C600/pYMS4514	pYMS4514 carries $yadA_{YPO3}$ and $lcrF_{YPO3}$ cloned into pTM100. Expresses YadA when grown at 37° C.	[32 ]
HB101/pPIL110-	The F7 <sub>1</sub> fimbrial gene cluster of <i>E. coli</i> AD110 cloned into pJB8	[33
HB101/pPKL4	Type 1 fimbrial gene cluster of E. coli cloned into pBR 322	[34
 HB101/pPIL110- 708	The F7 <sub>1</sub> (FSO) gene cluster of <i>E. coli</i> AD110 cloned into pBR 322	[35 ]

coli strains C600 and HB101 were grown overnight at 37°C on Luria agar. E. coli HB101/pPKL4, HB101/pPIL110-75 and HB101/pPIL110-708 were grown on Luria agar supplemented with 50 µg ampicillin per ml. The plate cultures were then suspended in 10 ml of phosphate buffered salaine, pH 7.4 (PBS). The liquid cultures and suspensions were centrifuged at 3000 rpm for 15 minutes, then the bacteria were resuspended into an appropriate amount of PBS to obtain an optical density of 600 nm (OD<sub>600</sub>)between 0.19 and 0.21. The corresponding bacterial concentration was determined by the dilution plating method. For Y. enterocolitica strains and E. coli C600 clones it was about  $2x10^8$ (cfu) per ml, and for E. coli HB101, HB101/pPKL4, HB101/pPIL110-75, and HB101/pPIL110-708 clones it was  $1.5x10^8$  cfu per ml. Different concentrations ( $10^{6}$ - $10^{9}$ per ml) were prepared from each of the bacterial suspensions. For the inhibition assays, each of the inhibitor solutions was added to 800 µl of one of bacterial suspensions, and the final volume was brought to one ml with PBS.

#### Proteins used

Collagen type I (C-7774) and IV (C-7521), from human placenta, laminin (L2020), from the basement membrane of Engelbreth-Holm-Swarm mouse sarcoma (1 mg per ml in 0.15 M NaCl, 0.05 M Tris solution), fibronectin (F-2006) and Bovine Serum Albumin (BSA, A-8022) were purchased from Sigma Chemical Company (St Louis, MO). Collagen was dissolved into 0.1 M acetic acid and fibronectin into distilled water to a concentration of 1 mg per ml. Further dilutions were made in PBS.

#### Preparation of frozen sections and coated slides

Small pieces of human colon removed surgically at Turku University Hospital, were immediately packed on ice for transportation to the laboratory, cut into smaller pieces (5-10mm) and frozen in blocks using O.C.T. compound (Miles Inc. Diagnostics Division, Elkhart, IN). Eight-micrometer frozen sections were cut from the blocks and mounted on sterile microscopic slides inside water repellent circles 2 cm in diameter drawn with a PAP pen (peroxidase anti peroxidase pen from Diado Sangyo Co. Ltd., Tokyo Japan). We prepared Lewis rat kidney sections similarly. We fixed the sections for 30 minutes in methanol containing 2%  $H_2O_2$ , washed them three times for 5 minutes with PBS, and kept them at -20°C till needed.

Glass slides were coated using different concentrations (1 ng-100  $\mu$ g per ml) of collagen type I, type IV or fibronectin by incubating the solutions inside water repellent circles for 16 hours at room temperature. Control circles were coated with BSA, at 30  $\mu$ g per ml. Circles were washed three times with PBS and used immediately.

## Enzyme immunoassay (EIA) detection method

To reduce the background reactivity, we used a two-step blocking procedure. Fixed tissue sections and coated circles were blocked first by immersing the whole slides in PBS-3% BSA for 30 minutes at room temperature. After three washings with PBS, the slides were incubated for 30 minutes at room temperature in a wet chamber, the circles overlaid with 100 µl of 10% sheep serum in PBS-3% BSA. In addition, the antibody dilutions were also made in 3% BSA-PBS. We did not test systematically other blocking procedures, however, omitting the sheep serum clearly increased the background level. The slides were washed three times, then the circles were overlaid with 100 µl of bacterial suspensions of different concentrations (10<sup>6</sup>-10<sup>9</sup> cfu per ml) and incubated under gentle rotation at 60 rpm. Incubation temperatures and times are given for each experiment individually in the results. Very long incubation times were not used since the 100  $\mu$ l droplets tend to dry even if the incubations take place in moist chambers. The unbound bacteria were poured away and the slides washed three times with PBS. For the Y. enterocolitica strains, the circles were overlaid with 100 µl of monoclonal antibody (Moab) A6, specific for the O-antigen of Y. enterocolitica serotype 0:3 [24], diluted 1:10 in PBS-3% BSA. For E. coli strains, the circles were overlaid with rabbit anti E. coli lysate polyspecific antibody (B 357, Dakopatts, Glostrup, Denmark), diluted 1:1000 in PBS-3% BSA. B357 has been produced in rabbits immunized with an aqueous extract of a sonicate of E. coli (non-transformed strain K12 C600). After three washings, the Y. enterocolitica circles were overlaid with 100 µl of peroxidase-conjugated rabbit anti-mouse immunoglobulins (Dakopatts P260) diluted 1:500 in PBS-3% BSA, and the E. coli circles with 100 µl peroxidase-conjugated swine anti-rabbit immunoglobulins (P 217 Dakopatts) diluted 1:1000 in PBS-3% BSA. We experimentally optimized the antibody concentrations to be used for relatively short incubation times (<30 min).

After three washings, the circles were overlaid for 10 minutes (depending on colour production) at room temperature with 100  $\mu$ l of EIA substrate solution freshly supplemented with 10  $\mu$ l of 30% H<sub>2</sub>O<sub>2</sub> per 15 ml of substrate solution. The EIA substrate solution contained 3 mg per ml of 1,2-phenylenediamine dissolved into citrate buffer (4,97 g citric acidxH<sub>2</sub>O+9,90 g Na<sub>2</sub>HPO<sub>4</sub>x2H<sub>2</sub>O dissolved into total of one litre distilled water). From each circle, 75  $\mu$ l of the substrate solution was pipetted into EIA plate wells (Dynatech Immulon,Roskilde, Denmark), and the reaction was stopped with 125  $\mu$ l of 1M HCl. The coloured product was recorded using a Labsystems Multiskan Plus

spectrophotometer at 492 nm. For each bacterial dose and experimental setting a minimum of four parallel sections or coated circles was used.

Non-specific binding to sections or coated circles was controlled in several ways: i) to control the non-specific binding of antibodies bacteria were omitted, ii) to control bacterial endogenous peroxidase activity, both antibodies were omitted, iii) to control non-specific binding of the conjugate, the primary antibodies were omitted. These controls showed that the background activity was always due to non-specific binding of the conjugate, and that there was no bacterial endogenous peroxidase activity present (data not shown).

#### **RESULTS AND DISCUSSION**

For measuring bacterial adhesion to a multitude of solid targets, three major approaches have been used. i) radiolabelled bacteria [10], ii) direct microscopic counting [7, 9, 25, 26], and iii) counting colony forming units [11, 13]. We previously used light microscopy in detecting localized bacterial binding on fixed tissue sections, [22]. The above techniques were not readily applicable for inhibition experiments. Thus we developed an EIA method which is based on immunological labelling of bound bacteria with peroxidase and detecting the bound label by colour production. In general, EIA methods have been widely used in a great number of microbiological applications [27], and the basic methodology is thoroughly tested. Usually the target is immobilized on a solid surface, such as a microtiter plate well; tissue sections have not, however, commonly been used as immobilized antigen.

To evaluate the general usefulness of the EIA detection method, we selected three known and well-documented adhesins for our studies (type 1 fimbriae, P fimbriae and the YadA protein) [19-22]. We performed a set of binding experiments with bacteria expressing these adhesins to confirm that the EIA method is applicable as an alternative way of studying bacterial binding and inhibition of binding to tissue sections or to extracellular matrix molecules.

All three adhesins have previously been shown to bind to tissue sections. P-fimbriated *E. coli* HB101/pPIL110-75 adheres to tissue sections of rat kidney [21], and HB101/pPIL110-75 and another *E. coli* strain, HB101/pPIL110-708, which has a deletion in the *pilA* gene [35], the major subunit of P-fimbriae, adhere strongly to immobilized fibronectin. *E. coli* HB101/pPKL4, expressing type 1 fimbriae binds to immobilised laminin [20]. Finally, *E. coli* C600/pYMS4514, as well as YeO3, expressing the *Yersinia* adhesin YadA, bind to tissue sections and to immobilized collagen, laminin and fibronectin [9,18, 19, 22]

# Application of commercial antisera for the detection of E. coli

First, we confirmed that the *E. coli* specific antiserum (B357) along with the conjugated antiserum (P217) could be used to detect all the *E. coli* strains irrespective of the binding phenotype of the bacteria. To this end, different numbers of *E. coli* C600, C600/pYMS4514, HB101/pPKL4 and HB101 were fixed on glass slides, and the B357-P217 combination was used for detection as described in Materials and Methods. All the strains gave dose-dependent absorbance readings similar to those previously obtained with glass-fixed *Y. enterocolitica* using Moab A6-P260 combination [22] (data not shown).

# Detection of specific binding of bacteria to fixed tissue sections

The EIA method was then used to monitor the binding of adhesin-expressing bacteria to tissue sections. To obtain statistically-significant results we routinely used at least four parallel sections for each experimental condition. We paid special care when preparing the frozen sections to make sure they were as uniform as possible. Also when pipetting the 100  $\mu$ l reagent droplets on the sections, we made sure that the droplets spread all over the targets leaving no dry areas.

Different concentrations of E. coli C600 and C600/pYMS4514 were incubated on fixed sections of human intestine and detected by EIA (Fig. 1A). As expected, only the YadAexpressing strain, C600/pYMS4514, bound to the sections, whereas the control strain,



Figure 1. EIA detection of bacterial binding to fixed tissue sections. Panel A, binding of E. coli C600 and C600/pYMS4514 to fixed human intestinal tissue sections. Bacteria, primary and secondary antibodies were incubated on the sections for 30 minutes each at  $22^{\circ}$ C. Panel B and C, binding of E. coli HB101, HB101(pPKL4) and HB101(pPIL110-75) to fixed rat kidney tissue sections. The bacterial suspensions were incubated on the sections for one hour at  $22^{\circ}$ C. Panel B shows the results of HB101(pPIL110-75) using logarithmic scale for both axes, and panel C, using actual absorbance values on y-axis (actual absorbance values are used in all other figures on y-axis), The primary and secondary antibodies were incubated for 30 minutes each at  $22^{\circ}$ C. Black columns represent the mean values obtained from four parallel sections, and the open columns, corresponding standard deviations. As background control, samples with no bacteria were also measured. In this and other figures, increasing bacterial or inhibitor concentrations are given on the X-axis, and EIA absorbances, on the Y-axis.

C600, did not. In another experiment, *E. coli* strains HB101, HB101/pPKL4, and HB101/pPIL110-75 were incubated on fixed rat kidney sections. EIA absorbance showed that HB101/pPKL4 and HB101/pPIL110-75, expressing type 1 and type P fimbriae respectively bound efficiently to the kidney sections whereas HB101 did not (Fig. 1B). These results are in good agreement with previous results on both YadA [19] and fimbriae-expressing *E. coli* strains [20, 21], and demonstrate for the first time that HB101 (pPKL4) binds to rat kidney.

In the three experiments described above, the assay sensitivity was  $\geq 10^5$  bacteria. We did not try to increase the sensitivity since bacteria could be detected on both fixed tissue sections and coated circles. Higher sensitivity, which might be needed when the binding target is very small, could be obtained by increasing the antibody incubation times and/or concentrations. However, increasing incubation times and antibody concentrations may also increase background, that is mostly caused by non-specific binding of antibodies.

The EIA-detection method allowed us to monitor bacterial binding to the fixed tissue sections over about a 100-fold range. There was a linear relationship between absorbance values and bacterial concentrations from about 5x10<sup>6</sup> to about 5x10<sup>8</sup> bacteria per ml. The linearity is seen in Fig. 1.B, where both the absorbance values and the bacterial concentrations are plotted on logarithmic scale. It should be noticed, however, that the relationship is not 1:1, i.e., 50 times more bacteria do not give 50-fold increase in absorbance, instead it was 10-20 fold. This inefficiency appears to be inherent in EIA based assays, and there may be many reasons for it. One reason could be that the method includes many reagents used in multiple steps, where the reaction conditions are not always optimal. This, especially with high concentration of antigenic epitopes combined with limiting antibody concentrations, may then lead to the apparent inefficiency. Another plausible reason may be steric hindrance when high bacterial concentrations are used. Bacterial cells binding to closeby receptors will block the antibody binding sites on each other; alternatively, especially with YadA-expressing bacteria, bacterial cells bind to each other with the same result. For this reason when performing EIA-based assays, quantification needs internal standards.



Figure 2. Effect of temperature on YadA-mediated YeO3 binding to fixed tissue sections of human intestine. Bacteria were incubated for 15 minutes at 4°C, 37°C, and 22°C. Incubation times for the primary and secondary antibodies were 15 minutes each at 22°C.

# Effect of incubation temperature on YadA-mediated binding

We used the EIA method to study the effect of incubation temperature on YadAmediated binding. Different concentrations of YeO3 and YeO3-c were incubated on fixed and blocked intestinal tissue sections at 4°C, 22°C or 37°C. The EIA absorbances showed that the YadA-mediated binding was not affected by the binding temperature (Fig. 2), suggesting that the affinity of the binding is exceptionally high, especially since the time allowed for the binding was only 15 minutes. YeO3-c showed no significant binding over the background at any temperature (data not shown).

#### Effect of incubation time on binding

The above results implied that the binding properties of the adhesin determine the binding parameters. To substantiate this we compared the effect of incubation time on the YadA and fimbriae-mediated binding. YeO3, and YeO3-c suspensions  $(2x10^8)$  were incubated on fixed and blocked intestinal tissue sections for 15, 60 and 120 minutes at



Figure 3. Panel A: effect of incubation time on binding of *E. coli* strains to tissue sections of rat kidney. Black columns, HB101(pPIL110-75); grey columns, HB101; white column, no bacteria. Incubation times for the primary and secondary antibodies were 30 minutes at 22°C. Panel B: effect of incubation time on binding of *Y. enterocolitica* strains to fixed tissue sections of human intestine at  $4^{\circ}$ C for 15, 60 and 120 minutes. Black columns, YeO3; grey columns, YeO3-c; white column, no bacteria. Incubation times for the primary and secondary antibodies were 15 minutes at  $22^{\circ}$ CColumns on top represent the standard deviations.

4°C. Under these conditions, the YadA-mediated binding apparently approached saturation already during the first 15 minutes of incubation; the EIA absorbance was only a little higher with an incubation time of 120 minutes (Fig. 3B). It should be noted, however that at these high readings, the absorbancies are above the linear range of the spectrophotometer. YeO3-c showed no binding even after 120 minutes incubation (Fig. 3B). The fimbriae-mediated binding to fixed and blocked rat kidney sections was tested using HB101/pPIL110-75, and HB101 as control. Fimbriae-mediated binding is much slower than YadA-mediated binding (Fig. 3A); the binding reached saturation only after the first hour of incubation.



## APPLICATION OF AN ENZYME IMMUNOASSAY

In summary, we found that on fixed tissue sections, YadA-mediated binding is very strong and rapid, whereas fimbriae-mediated binding is much weaker and slower under the condition we studied. For binding experiments with YadA, 15 min incubation time was sufficient whereas with fimbriae, 1 h was needed.

# Bacterial adherence to glass slides coated with extracellular matrix molecules.

We then used the EIA method to monitor bacterial binding to glass circles coated with target molecules. To determine a functional coating concentration, adhesive bacteria  $(2x10^8 \text{ cfu per ml})$  were incubated on circles coated with different concentrations of target proteins. Coating concentrations of 10 µg per ml proved to be sufficient for EIA detection (data not shown). Our method could detect YadA-mediated binding to collagen type I coated circles (Fig. 4A), YadA-mediated binding to collagen type1V coated circles (Fig. 4B), and P fimbriae-mediated binding to fibronectin coated circles (Fig. 4C).

These results are in good agreement with previous findings of YadA- and P-fimbriaemediated binding to type I and IV collagens and to fibronectin [19, 21, 22], and demonstrate that the EIA method provides an alternative way of studying the binding of bacteria to immobilised extracellular matrix molecules.

In all these experiments, the control circles coated with BSA showed low level dose dependent binding (See Fig. 4A). We do not know the reason, perhaps the BSA preparations are contaminated with minor amounts of extracellular matrix molecules.

#### Inhibition experiments with extracellular matrix molecules

The EIA method proved most useful in competition experiments. We could detect dosedependent inhibition of YadA-mediated binding of YeO3 to tissue sections of human

Figure 4. EIA detection of bacterial adhesion to glass slide circles coated with extracellular matrix molecules. For panels A and B, bacteria were incubated on circles for 30 minutes at  $22^{\circ}$ C, and incubation times for both primary and secondary antibodies were 15 minutes at  $22^{\circ}$ C. For panel C, bacteria were incubated on circles for one hour at  $22^{\circ}$ C, and incubation times for both primary antibodies were 30 minutes at  $22^{\circ}$ C. Columns are as in Fig. 1 and binding to BSA coated circles is shown by grey columns. Panel A: binding of YeO3 and YeO3-c to immobilised collagen type I. Panel B: binding of *E. coli* C600 and C600/pYMS4514 to immobilised collagen type IV. Panel C: binding of *E. coli* HB101, HB101(pPIL110-708) to immobilised fibronectin.



Figure 5. EIA detection of inhibition by collagen type I of YadA-mediated binding to fixed and blocked tissue sections of human intestine. YeO3  $(2x10^8/ml)$  was preincubated with different concentrations of collagen type I for 30 minutes at 37°C before incubation on sections for 15 minutes at 4°C. Incubation times for primary and secondary antibodies were 15 min at 22°C. Each point represents the mean of four parallel sections and the vertical bars show the corresponding standard deviations.

intestine by collagen type I (Fig. 5). We also measured the inhibition of binding to glassimmobilized extracellular matrix molecules. Using, for instance, collagen type I immobilized on glass slides as a target and two different concentrations,  $10^7$  and  $10^8$  per ml, of YeO3 (Fig. 6A). Again, there was clear dose-dependent inhibition of binding, similar to the inhibition of binding to tisssue sections of human intestine (Fig. 5), suggesting that collagen is an important receptor for YadA in the intestine.

Inhibition of YadA-mediated binding was further studied using E. coli C600 and C600/pYMS4514. As YadA binds both collagen and laminin, we attempted to inhibit the binding to immobilized collagen type IV by both. Binding was inhibited by collagen but not



Figure 6. EIA detection of inhibition of YadA-mediated binding to coated circles. Panel A: YeO3 (open circles, 10<sup>7</sup>, filled circles, 10<sup>8</sup> bacteria per ml) was preincubated for 30 minutes at 37°C with different concentrations of collagen type I before incubation on coated circles for 30 minutes at 22°C. Panel B: C600/pYMS4514 (2x10<sup>8</sup>/ml) was preincubated for 30 minutes at 37°C with soluble collagen IV (open circles) or soluble laminin (filled circles) at different concentrations before incubation on collagen type IV coated circles for 30 minutes at 22°C. Incubation times for the primary and secondary antibodies were 30 minutes.

by laminin (Fig 6B), indicating that the collagen and laminin binding domains of YadA are discrete.

# **CONCLUSION**

The new enzyme immunoassay method is a rapid and reliable technique for measuring bacterial adherence to fixed tissue sections and to immobilized extracellular matrix molecules on glass slides. The advantages of the technique are i) it is reliable, evidenced by small standard deviations and by highly significant binding inhibition experiments. ii) it is rapid; one experiment can be performed in six hours. iii) it is flexible, allowing monitoring of bacteria bound both to non-uniform targets, such as fixed sections, and to coated surfaces.

A potential drawback is the requirement for a primary antibody specific for the bacterial species under investigation. Borén and coworkers [28] used digoxigenin-labelled *Helicobacter pylori* bacteria to study binding to gastric tissues. This labelling system coupled with detection using enzyme labelled anti-digoxigenin antibodies could also be a good choice with bacteria where no bacteria-specific antibodies are available. It must be kept in mind, however, that the labelling procedure may affect the bacterial adhesin *per se* and interfere with the binding. This does not occur with specific antibodies that are added after the bacteria are bound to their targets.

## ACKNOWLEDGEMENTS

The authors thank Dr. Benita Westerlund (University of Helsinki) for her kind gift of fimbriae-expressing strains, and for comments on the manuscript. Ms. Eija Nordlund is acknowledged for drawing the figures. This work was supported by grants from the Sigrid Jusélius Foundation, the Turku University Foundation, the Academy of Finland and the Arab Student Aid International Foundation. The language was revised by Dr. Adrian Goldman

Corresponding author: Dr. Yasmin El Tahir Turku Centre for Biotechnology and Åbo Acadamy University P.O. Box 123, FIN -20521 Turku, Finland Telephone: +358-(0)2-3338010 Telefax: +358-(0)2-333 8000 Electronicmailaddress:yeltahir@.btk.utu.fi

# APPLICATION OF AN ENZYME IMMUNOASSAY

#### REFERENCES

[1] Doig, P. and Trust, T.J. Methodological approaches of assessing microbial binding to extracellular matrix components. J. Microbiol. Methods. 1993; 18: 167-80.

[2] Skurnik, M. and Wolf-Watz, H. Analysis of the *yopA* gene encoding the Yop1 virulence determinants of *Yersinia* spp. Mol. Microbiol. 1989; 3: 517-29.

[3] Kapperud, G., Namork, E., Skurnik, M. and Nesbakken, T. Plasmid-mediated surface fibrillae of *Yersinia pseudotuberculosis* and *Yersinia enterocolitica*: Relationship to the outer membrane protein YOP1 and possible importance for pathogenesis. Infect. Immun. 1987; 55: 2247-54.

[4] Krogfelt, K.A. Bacterial adhesion-genetics, biogenesis, and role in pathogenesis of fimbrial adhesins of *Escherichia Coli*. Rev. Infect. Dis. 1991; 13: 721-35.

[5] Lee, W.H., McGrath, P.P., Carter, P.H. and Eide, E.L. The ability of some Yersinia enterocolitica strains to invade HeLa cells. Can. J. Microbiol. 1977; 23: 1714-22.

[6] Une, T. Studies on the pathogenicity of *Yersinia enterocolitica*. I. Experimental infection in rabbits. Microbiol. Immunol. 1977; 21: 349-63.

[7] Devenish, J.A. and Schiemann, D.A. HeLa cell infection by *Yersinia enterocolitica*: evidence for lack of intracellular multiplication and development of a new procedure for quantitative expression of infectivity. Infect. Immun. 1981; 32: 48-55.

[8] Lassen, J. and Kapperud, G. Serotype-related HEp-2 cell interaction of Yersinia enterocolitica. Infect. Immun. 1986; 52: 85-89.

[9] Heesemann, J. and Grüter, L. Genetic evidence that the outer membrane protein YOP1 of *Yersinia enterocolitica* mediates adherence and phagocytosis resistance to human epithelial cells. FEMS Microbiol. Lett. 1987; 40: 37-41.

[10] Schiemann, D.A., Crane, M.R. and Swanz, P.J. Surface properties of *Yersinia* species and epithelial cell interactions *in vitro* by a method measuring total associated, attached and intracellular bacteria. J. Med. Microbiol. 1987; 24: 205-18.

[11] Rosqvist, R., Skurnik, M. and Wolf-Watz, H. Increased virulence of Yersinia pseudotuberculosis by two independent mutations. Nature 1988; 334: 522-25.

[12] Miller, V.L. and Falkow, S. Evidence for two genetic loci in *Yersinia enterocolitica* that can promote invasion of epithelial cells. Infect. Immun. 1988; 56: 1242-48.

[13] Isberg, R.RPathways for the penetration of enteroinvasive *Yersinia* into mammalian cells. Mol. Biol. Med. 1990; 7: 73-82.

[14] Powell, E., Hamers, A.M., Bergmans, H.E.N., Van der Zeijst, B.A.M. and Gaastra, W. Adhesion of canine and human uropathogenic *Escherichia coli* and *Proteus mirabilis* strains to canine and human epithelial cells. Curr. Microbiol. 1988; 17: 333-37.

[15] Schaeffer, A.J., Amudsen, S.K. and Schmidt, L.N. Adherence of *Escherichia coli* to human urinary tract epithelial cells. Infect. Immun. 1979; 24: 753-59.

[16] Väisänen-Rhen, V., Rhen, M., Linder, E. and Korhonen, T.K. Adhesion of *Escerichia coli* to human kidney cryostat sections. FEMS Microbiol. lett. 1985; 27: 179-82.

[17] Nowicki, B., Holthöfer, H., Sareneva, T., Rhen, M. V., Väisänen-Rhen. and Khorhonen, T.K. Location of adhesion sites for P-fimbriated and 075X-positive *Escherichia coli* in the human kidney. Microb. Pathogen. 1986; 1: 169-80.

[18] Tertti, R., Skurnik, M., Vartio, T. and Kuusela, P. Adhesion protein YadA of *Yersinia* species mediates binding of bacteria to fibronectin. Infect. Immun. 1992; 60: 3021-24.

[19] Tamm, A., Tarkkanen, A.M., Korhonen, T.K., Kuusela, P., Toivanen, P. and Skurnik, M. Hydrophobic domains affect the collagen-binding specificity and surface polymerization as well as the virulence potential of the YadA protein of *Yersinia enterocolitica*. Mol. Microbiol. 1993; 10: 995-1011.

[20] Kukkonen, M., Raunio, T., Virkola, R. et al. Basement membrane carbohydrate as a target for bacterial adhesion - Binding of type-I-fimbriae of Salmonella enterica and Escherichia coli to laminin. Mol. Microbiol. 1993; 7: 229-37.

[21] Westerlund, B., van Die, I., Kramer, C., et al Multifunctional nature of P fimbriae of uropathogenic *Escherichia coli*: mutations in *fsoE* and *fsoF* influence fimbrial binding to renal tubuli and immobilized fibronectin. Mol. Microbiol. 1991; 5: 2965-75.

[22] Skurnik, M., El Tahir, Y., Saarinen, M., Jalkanen, S. and Toivanen, P. YadA mediates specific binding of enteropathogenic *Yersinia enterocolitica* to human intestinal submucosa. Infect. Immun. 1994; 62: 1252-61.

[23] Skurnik, M. Expression of antigens encoded by the virulence plasmid of Yersinia enterocolitica under different growth conditions. Infect. Immun. 1985; 47: 183-90.

[24] Pekkola-Heino, K., Viljanen, M.K., Ståhlberg, T.H. Granfors, K. and Toivanen, A. Monoclonal antibodies reacting selectively with core and O-polysaccharide of *Yersinia enterocolitica* O:3 lipopolysaccharide. APMIS. 1987; 95: 27-34.

[25] Jones, G.W. and Rutter, J.M. Role of the K88 antigen in the pathogenesis of neonatal diarrhea caused by *Escherichia coli* in piglets. Infect. Immun. 1972; 6: 918-27.

[26] Paerregaard, A., Espersen, F. and Skurnik, M. Role of *Yersinia* outer membrane protein YadA in adhesion to rabbit intestinal tissue and rabbit intestinal brush border membrane vesicles. APMIS. 1991; 99: 226-32.

[27] Voller, A. and Bidwell, D. Enzyme-linked immunosorbent assay. In: Manual of clinical laboratory immunology (Rose, N.R., Friedman, H. & Fahey, J.L., eds.) American Society for Microbiology, Washington, D.C. 1986.

[28] Borén, T., Falk, P., Roth, K.A., Larson, G. and Normark, S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. Science. 1993; 262: 1892-95.

[29] Skurnik, M. Lack of correlation between the presence of plasmids and fimbriae in *Yersinia enterocolitica* and *Yersinia pseudotuberculosis*. J. Appl. Bacteriol. 1984; 56: 355-63.

[30] Appleyard, R.K. Segregation of new lysogenic types during growth of doubly lysogenic strain derived from *Escherichia coli* K12. Genetics. 1954; 39: 440-52.

[31] Boyer, H. W. and Roland-Dussoix, DA complementation analysis of restriction and modification of DNA in *Escherichia coli*. J. Mol. Biol. 1969; 41: 459-72.

[32] Skurnik, M. and Toivanen, P. LcrF is the temperature-regulated activator of the yadA Gene of Yersinia enterocolitica and Yersinia pseudotuberculosis. J. Bacteriol. 1992; 174: 2047-51.

[33] Van Die, I., Spierings, G., Van Megan, I., Zuidweg, E., Hoekstra, W. and Bergmans, H. Cloning and genetic organization of the gene cluster encoding F71 fimbriae of a uropathogenic *Escherichia coli* and comparison with the F72 gene cluster. FEMS Microbiol. lett. 1985; 28: 329-34.

[34] Klemm, P., Jörgensen, J.B., Van Die, I., de Ree, H. and Bergmans, H. The *fim* genes responsible for synthesis of type 1 fimbriae in *Escherichia coli*, cloning and genetic organization. Mol. Gen.Genet. 1985; 199: 410-14

[35] Riegman, N., Van Die, I., Leunissen, J., Hoekstra, W. and Bergmans, H. Biogenesis of F71 and F72 fimbriae of uropathogenic *Escherichia coli*: influence of the FsoF and FstFG proteins and localization of the Fso/FstE protein. Mol. Microbiol. 1988: 2 1, 73-80